AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 24 - (NewsRx.com & NewsRx.net) -- A review article in the Lancet assesses the impact of BRCA1 gene mutations - known to be strongly associated with an increased risk of breast and ovarian cancer - on the management of patients.
The BRCA1 gene was identified in 1990 and cloned in 1994. Around 1 in 500 to 1 in 800 women have a BRCA1 gene mutation; women with familial breast or ovarian cancer have a germline mutation of the gene, which gives them a lifetime risk of breast cancer of around 50-85%, and ovarian cancer of 15-60%. Although a genetic test for identification of high-risk individuals has been developed, the underlying mechanisms of how inactivation of the BRCA1 gene leads to malignant cell growth is not fully understood. .
Paul Harkin and Richard Kennedy from Queens University, Belfast, and colleagues examined the mechanisms that underlie inactivation of BRCA1 and assessed how they affected the management of patients, in terms of both primary (e.g., prophylactic surgery such as mastectomy or oopherectomy and preventative use ...